CPT® Code 87324

Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; Clostridium difficile toxin(s)

The CPT® Code 87324 refers to a laboratory test designed to detect the presence of Clostridium difficile toxin antigen in a fecal sample using various immunoassay techniques. Clostridium difficile, often abbreviated as C. difficile, is a bacterium that resides in the colon and can produce toxins that lead to serious gastrointestinal diseases, particularly when present in significant quantities. This organism is recognized as the leading cause of bacterial diarrhea among hospitalized patients and is frequently associated with the use of antimicrobial drugs, which can disrupt normal gut flora and allow C. difficile to proliferate. The test can be performed using several immunoassay methods, including enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), fluorescence immunoassay (FIA), and immunochemiluminometric assay (IMCA). In practice, a fecal sample is collected and either preserved in a fixative or sent fresh to the laboratory for analysis. The EIA and ELISA techniques are particularly sensitive, capable of detecting minute quantities of the antigen by utilizing a specific antibody that binds to the antigen in the sample. A secondary enzyme-labeled antibody is then introduced, which facilitates the detection of the antigen-antibody complex through a chromogenic reaction, resulting in a visible color change or fluorescence that indicates the presence of the toxin. The results can be reported as qualitative, indicating the presence or absence of the antigen, or semi-quantitative, providing a measure of the antigen concentration based on colorimetric readings. The FIA method employs a fluorescent compound to detect the binding of the detection antibody to the analyte, while the IMCA method utilizes antibodies tagged with a chemiluminescent substance to identify and quantify the antigen-antibody complex through emitted light. This comprehensive approach to testing is crucial for diagnosing infections caused by C. difficile and guiding appropriate treatment strategies.